Altre lingue Solvonis Therapeutics plc

Azioni

SVNS

GB00BMD1Z199

Biotecnologia

Mercato chiuso - London S.E. Altri mercati azionari 17:35:21 15/12/2025			Variaz. 5gg	Var. 1 gen.
0,2400 ^GBX	-4,00%		-11,11%	+17,07%

03/12	Solvonis accoglie con favore l'approvazione del programma statunitense per il composto contro le dipendenze	AN
03/12	Agenzia Governativa Statunitense Avvierà Test Preclinici su SVN-015 per il Trattamento delle Dipendenze	MT

Altre lingue

Solvonis hails US discovery programme approval for addiction compound	03/12
Solvonis Says US Government Agency to Conduct Preclinical Test of SVN-015 for Addiction Treatment	03/12
Hansa rises; Ondo InsurTech loss widens	03/12
Solvonis Therapeutics says NIDA to fund early preclinical evaluation of SVN-015	03/12
Solvonis Therapeutics Completes Corporate Restructuring	31/10
Solvonis Therapeutics completes corporate restructuring actions	31/10
Solvonis Therapeutics plc Announces Incorporation of New R&D Entities in the UK and US to Enhance Global Research Framework	31/10
Solvonis Therapeutics plc Appoints Paul Carter as Non-Executive Director, Effective 27 October 2025	27/10
Gelion plans fund raise alongside testing agreement	16/10
EARNINGS: GENinCode sees annual revenue growth slower than expected	30/09
Solvonis Therapeutics plc Reports Earnings Results for the Half Year Ended June 30, 2025	30/09
Avingtrans HS2 win; Metals Exploration's Runruno blow	28/08
Solvonis shares jumps as touts positive results at PTSD therapy trials	12/08
S&U hails motor finance verdict; Xaar down	12/08
Solvonis Therapeutics plc Announces Positive Results from Pre-Clinical Screening in its SVN-SDN-14 Programme	12/08
Solvonis Therapeutics Starts Translational Studies for Alcohol-use Disorder Treatment	22/07
Solvonis Therapeutics initiates studies for SVN-002 to support 505(b)(2) pathway and advance towards phase 2b trial	22/07
Solvonis Therapeutics plc Announces the Initiation of Key Translational Studies to Support the Advancement of SVN-002 Towards A Planned Phase 2B Clinical Trial in the United States	22/07
Stocks red as "real concerns" on tariffs remain	11/07
Solvonis raises GBP1 million at premium	11/07
Solvonis Therapeutics raises GBP1.0 million for drug discovery scheme	11/07
Solvonis Therapeutics Raises GBP1 Million via Share Subscription	11/07
Solvonis Therapeutics announces £1 mln subscription to accelerate AI drug discovery	11/07
Solvonis Therapeutics Gets US Patent Allowance for New Morpholine-class Compounds	23/06
Solvonis Therapeutics plc Announces Allowance of U.S. Patent Covering AI-Supported CNS Discovery Programme Compounds	23/06

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Trascrizioni Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Solvonis Therapeutics plc

Azioni

SVNS

GB00BMD1Z199

Biotecnologia

Altre lingue

Filtri